The role of overexpressed HER2 in transformation

Annals of Oncology

Volumn 12, Issue SUPPL. 1, 2001, Pages

  Neve, R M ^a   Lane, H A ^a   Hynes, N E ^a  

^a FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

Author keywords

Breast cancer; erbB 2; HER2; New; Receptor over expression; Tyrosine kinase activity

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 3; MONOCLONAL ANTIBODY; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER THERAPY; CARCINOGENESIS; CELL DIFFERENTIATION; CELL GROWTH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; SIGNAL TRANSDUCTION; TUMOR CELL;

EID: 0034873386     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/12.suppl_1.S9     Document Type: Article

References (34)

1. The basic biology of HER2
2. 3 cells
3. 3 cells
4. 3 cells
5. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
6. Transformation mediated by the human HER-2 gene independent of epidermal growth factor receptor
7. Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: Correlation with steroid receptors
8. ERBB2 amplification in breast cancer with a high rate of proliferation
9. Follow up study of HER-2/neu amplification in primary breast cancer
10. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer
11. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading
12. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
13. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies
14. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185
15. The biology of erbB-2/neu/HER-2 and its role in cancer
16. Growth factors and cancer
17. The HER2(c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast
18. The significance of oncogene amplification in primary breast cancer
19. HER-2 overexpression, and its intratumor heterogeneity in human breast cancer
20. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs
21. Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: Immunohistological assessment correlates with gene amplification
22. Intracellular expression of single chain antibodies reverts ErbB-2 transformation
23. Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling
24. Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells
25. HER2 monoclonal antibody has antiproliferative effects in vitro and sensitises human breast tumor cell to tumor necrosis factor
26. Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells
27. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks cross-talk with growth factor receptors
28. Effects of the 4D5 antibody on HER2/neu heterodimerization with other class I receptors in human breast cancer cells
29. Neutralizing antibodies against epidermal growth factor and erbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic signal transduction therapy of solid tumors
30. Kip1-Cdk2 complex formation: Receptor overexpression does not determine growth factor dependency
31. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
32. Recombinant humanized anti-HER2 antibody (Herceptin®) enhances the antitumour activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
33. HER2/neu monoclonal antibody plus cisplatin in to chemotherapy treatment
34. Cancer statistics